{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:53:35Z","timestamp":1777514015287,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Objectives:<\/jats:title>\n                    <jats:p>Actinic keratoses (AK) are premalignant skin lesions caused by chronic sun exposure, topically managed by 5-fluorouracil (5-FU), diclofenac 3% gel, and imiquimod. Despite their effectiveness, long treatment duration and severe adverse local skin reactions have limited patient concordance. Calcipotriol has recently been used as a combination agent for existing topical AK treatments. A systematic review was performed to determine the clinical efficacy of 5-FU and calcipotriol for the treatment of AK, Bowen\u2019s disease, and squamous cell carcinoma (SCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature search was conducted on Medline, Embase, and Cochrane Library. Among the 84 records screened, 12 were retrieved for full-text review and 8 were included in the final analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the 8 studies, there were 214 control patients and 288 patients who received the intervention. The combination 5% 5-FU with calcipotriol resulted in a significant reduction in the number of AKs on the face, scalp, right upper extremity, and left upper extremity for all sites at 8 weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .0001). No significant difference in SCC incidence was observed at 1 or 2 years, but there was a significant reduction observed at 3 years for SCC on face and scalp. No study assessed the combination for Bowen\u2019s disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Combination 5% 5-FU with calcipotriol is an effective treatment for Aks; however, future trials may consider longer treatment and follow-up periods for the treatment and prevention of AK, SCC in situ, and SCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/12034754241256347","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T01:15:58Z","timestamp":1716513358000},"page":"375-380","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen\u2019s Disease, and Squamous Cell Carcinoma: A Systematic Review"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0110-2813","authenticated-orcid":false,"given":"Adam H.","family":"Lapidus","sequence":"first","affiliation":[{"name":"Department of Dermatology, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangho","family":"Lee","sequence":"additional","affiliation":[{"name":"Monash School of Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-1919","authenticated-orcid":false,"given":"Zhao Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Smithson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Y.","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Alfred Health, Melbourne, VIC, Australia"},{"name":"Monash School of Medicine, Monash University, Melbourne, VIC, Australia"},{"name":"Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Gin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1997.tb01004.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02560.x"},{"key":"e_1_3_3_4_2","volume-title":"Non-Melanoma Skin Cancer: General Practice Consultations, Hospitalisation and Mortality","author":"Australian Institute of Health and Welfare","year":"2008","unstructured":"Australian Institute of Health and Welfare. Non-Melanoma Skin Cancer: General Practice Consultations, Hospitalisation and Mortality. Australian Institute of Health and Welfare; 2008."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.17061\/phrp3212203"},{"key":"e_1_3_3_6_2","volume-title":"Cancer Data in Australia","author":"Australian Institute of Health and Welfare","year":"2022","unstructured":"Australian Institute of Health and Welfare. Cancer Data in Australia. Australian Institute of Health and Welfare; 2022."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14767"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1178372"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125476"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89820"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06199-x"},{"key":"e_1_3_3_13_2","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JAC","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100104"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.010"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.027"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000508933"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.07.012"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18144"},{"issue":"2","key":"e_1_3_3_21_2","first-page":"22","article-title":"Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients","volume":"1","author":"Werschler WP","year":"2008","unstructured":"Werschler WP. Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol. 2008;1(2):22-27.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.08.017"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604575103"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2710"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12822"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024040"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700264"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0502"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221143091"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020225"},{"issue":"3","key":"e_1_3_3_32_2","first-page":"285","article-title":"0.5% 5-fluorouracil\/10% salicylic acid for the treatment of distal actinic keratoses under daily practice conditions","volume":"18","author":"Iglesias-Puzas A","year":"2019","unstructured":"Iglesias-Puzas A, Batalla A, Suh-Oh HJ, Fl\u00f3rez A. 0.5% 5-fluorouracil\/10% salicylic acid for the treatment of distal actinic keratoses under daily practice conditions. J Drugs Dermatol. 2019;18(3):285-288.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.047"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00919-0"},{"issue":"3","key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ddg.14048","article-title":"S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma\u2014short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators","volume":"18","author":"Heppt MV","year":"2020","unstructured":"Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma\u2014short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18(3):275-294.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"e_1_3_3_37_2","first-page":"399","article-title":"Cutaneous cryosurgery for common skin conditions","volume":"101","author":"Clebak KT","year":"2020","unstructured":"Clebak KT, Mendez-Miller M, Croad J. Cutaneous cryosurgery for common skin conditions. Am Fam Physician. 2020;101(7):399-406.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14106"},{"issue":"5","key":"e_1_3_3_39_2","first-page":"255","article-title":"Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis","volume":"94","author":"Hoover WD","year":"2014","unstructured":"Hoover WD3rd, Jorizzo JL, Clark AR, Feldman SR, Holbrook J, Huang KE. Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis. Cutis. 2014;94(5):255-259.","journal-title":"Cutis"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.7.813"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811850"},{"key":"e_1_3_3_42_2","first-page":"059","article-title":"Topical 5% fluorouracil (5-FU) prescribing practices for the treatment of actinic keratosis, sun damage and superficial non-melanoma skin cancers at an Australian tertiary teaching hospital","volume":"6","author":"Velik C","year":"2020","unstructured":"Velik C, Marshman G. Topical 5% fluorouracil (5-FU) prescribing practices for the treatment of actinic keratosis, sun damage and superficial non-melanoma skin cancers at an Australian tertiary teaching hospital. J Clin Dermatol Ther. 2020;6:059.","journal-title":"J Clin Dermatol Ther"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241256347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754241256347","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241256347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:50:44Z","timestamp":1777391444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754241256347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/12034754241256347"],"URL":"https:\/\/doi.org\/10.1177\/12034754241256347","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}